Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in June 2014 on request of the Sponsor.
On 18 December 2002, orphan designation (EU/3/02/126) was granted by the European Commission to Dyax s.a., Belgium, for recombinant inhibitor of human plasma kallikrein for the treatment of angioedema.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
Recombinant inhibitor of human plasma kallikrein
|Disease / condition||
Treatment of angioedema
|Date of first decision||
|EU designation number||
Sponsor's contact details
Tel. +32 87 688118
Fax +32 87 688918
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.